Abstract 417P
Background
Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. Limited knowledge exists on the expression and clinical meaning of miR-21 in extracellular vesicles (EVs) of breast cancer (BC) patients. Thus, the aim of this study has been to assess EV-derived miR-21 expression in different BC subsets.
Methods
One hundred women were enrolled: 30 with early BC, 30 with metastatic BC on treatment progression, 30 cancer survivors on follow up and 10 healthy controls matched for age and BMI. EVs, isolated from serum samples, were characterized by nanoparticle tracking analyzer (NTA), scanning electron microscopy (SEM) and atomic force microscopy (AFM) to detect their concentration, size and structure. The miR-21 in EVs was evaluated by Real Time PCR. The expression of miR-21 was compared between groups by calculating the ΔΔCt statistic and the fold change, considering miR-16 as the housekeeping gene. The ΔΔCt was calculated using a linear mixed model approach with gene x group interaction as the parameter of interest, adjusting for age, BMI and menopausal status, and considering random intercept and random slope terms to account for individual variability.
Results
No differences in EVs size and concentration among the four groups were detected. Considering the early BC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 expression. Higher expression of miR-21 has been found in metastatic versus healthy controls (p= 0.029 95% CI -1.549 to -0.079), mainly in HER2+ and hormone receptor positive patients (p 0.0005 and 0.036, respectively). In particular, in HER2+ miR-21 was significantly higher in patients with active BC (early and metastatic) (p 0.002 95% CI -1,707 to -0,376) compared to control group.
Conclusions
While further investigations shall be requested, our data on serum EV suggest that miR-21 may become a promising biomarker for early diagnosis and tumor activity, mainly in HER2+ BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Claudia Omarini.
Funding
MIUR Dipartimenti Eccellenti 2022.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15